{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:53:08Z","timestamp":1788807188464,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1). Tesamorelin, a growth hormone\u2013releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This 6-month phase 2 randomized open-label clinical trial compared tesamorelin vs standard of care (SOC) for NCI in people with HIV who were virally suppressed and abdominally obese (elevated waist circumference [WC]). Exclusions included conditions other than HIV causing NCI, active substance use disorder, and malignancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-three participants were randomized 3:2 to tesamorelin or SOC (2\u2005mg subcutaneously daily). The primary outcome was the change in neurocognitive performance at 6 months, with secondary outcomes including WC, mood, and daily functioning. The groups were well matched at baseline. The tesamorelin group showed a trend toward improved neurocognitive performance after 6 months (mean change, 0.146; 95% CI, \u2212.002 to .294; P = .060) while the SOC group did not (0.103; 95% CI, \u2212.095 to .301; P = .295), but the between-group difference was not significant (P = .673). IGF-1 levels increased, but changes did not correlate with summary regression change score or WC. The tesamorelin group had a greater reduction in WC than the SOC group (median difference, \u22122.7\u2005cm; P = .015).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While tesamorelin reduced WC, the cognitive benefits did not significantly differ between groups. Recognizing the limitations of insufficient power and no placebo arm, this study suggests no clear benefit of short-term AO reduction with tesamorelin on NCI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf012","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T17:53:31Z","timestamp":1736963611000},"page":"1230-1238","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-752X","authenticated-orcid":false,"given":"Ronald J","family":"Ellis","sequence":"first","affiliation":[{"name":"Department of Psychiatry"},{"name":"Department of Neurosciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Vaida","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Hu","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health and Human Longevity Science, University of California , San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dube","sequence":"additional","affiliation":[{"name":"AIDS Healthcare Foundation , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brook","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Psychiatry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K","family":"Heaton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2959-890X","authenticated-orcid":false,"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[{"name":"AIDS Healthcare Foundation , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Sattler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Southern California , Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2025060208125618100_jiaf012-B1","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1089\/aid.2018.0279","article-title":"Neurocognitive impairment in well-controlled HIV-infected patients: a cross-sectional study","volume":"35","author":"Portilla","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025060208125618100_jiaf012-B2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/09540121.2021.1891191","article-title":"Youth perinatal HIV-associated neurocognitive disorders: association with functional impairment","volume":"34","author":"Phillips","year":"2021","journal-title":"AIDS Care"},{"key":"2025060208125618100_jiaf012-B3","doi-asserted-by":"crossref","first-page":"e35652","DOI":"10.1097\/MD.0000000000035652","article-title":"HIV-related neurocognitive disorders: diagnosis, treatment, and mental health implications: a review","volume":"102","author":"Elendu","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"2025060208125618100_jiaf012-B4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/cid\/ciab655","article-title":"Higher comorbidity burden predicts worsening neurocognitive trajectories in people with human immunodeficiency virus","volume":"74","author":"Ellis","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025060208125618100_jiaf012-B5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41582-023-00879-y","article-title":"Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management","volume":"19","author":"Ellis","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"2025060208125618100_jiaf012-B6","doi-asserted-by":"crossref","first-page":"102677","DOI":"10.1016\/j.nicl.2021.102677","article-title":"Connectome-based prediction of global cognitive performance in people with HIV","volume":"30","author":"Yang","year":"2021","journal-title":"Neuroimage Clin"},{"key":"2025060208125618100_jiaf012-B7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/QAI.0000000000000458","article-title":"Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation","volume":"68","author":"Sattler","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025060208125618100_jiaf012-B8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1212\/WNL.0b013e3182478d64","article-title":"Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder","volume":"78","author":"McCutchan","year":"2012","journal-title":"Neurology"},{"key":"2025060208125618100_jiaf012-B9","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/cid\/ciad265","article-title":"Antiretroviral therapy intensification for neurocognitive impairment in human immunodeficiency virus","volume":"77","author":"Letendre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025060208125618100_jiaf012-B10","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2010-0490","article-title":"Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data","volume":"95","author":"Falutz","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2025060208125618100_jiaf012-B11","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/cid\/cis251","article-title":"Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin","volume":"54","author":"Stanley","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025060208125618100_jiaf012-B12","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1074\/jbc.274.14.9828","article-title":"Insulin-like growth factor-1\u2013mediated neuroprotection against oxidative stress is associated with activation of nuclear factor \u03baB","volume":"274","author":"Heck","year":"1999","journal-title":"J Biol Chem"},{"key":"2025060208125618100_jiaf012-B13","first-page":"009","article-title":"Prospective role of \u03b2-cell-specific IGF-1 for oxidative stress in the pathogenesis of diabetic neuropathy","volume":"S5","author":"Usuki","year":"2012","journal-title":"J Diabetes Metab"},{"key":"2025060208125618100_jiaf012-B14","doi-asserted-by":"crossref","first-page":"672392","DOI":"10.3389\/fphar.2021.672392","article-title":"Early IGF-1 gene therapy prevented oxidative stress and cognitive deficits induced by traumatic brain injury","volume":"12","author":"Montivero","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025060208125618100_jiaf012-B15","author":"Gustafsson"},{"key":"2025060208125618100_jiaf012-B16","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/db14-0568","article-title":"Insulin action in brain regulates systemic metabolism and brain function","volume":"63","author":"Kleinridders","year":"2014","journal-title":"Diabetes"},{"key":"2025060208125618100_jiaf012-B17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1210\/jcem.84.2.5455","article-title":"Insulin-like growth factor-I and cognitive function in healthy older men","volume":"84","author":"Aleman","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2025060208125618100_jiaf012-B18","doi-asserted-by":"crossref","first-page":"S514","DOI":"10.1016\/j.jalz.2011.05.1439","article-title":"Tesamorelin, a growth hormone-releasing hormone analogue, improves cognitive function in MCI and healthy aging: results of a randomized controlled trial","volume":"7","author":"Baker","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2025060208125618100_jiaf012-B19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2014a new world-wide definition. A consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"2025060208125618100_jiaf012-B20","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","article-title":"HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy","volume":"75","author":"Heaton","year":"2010","journal-title":"Neurology"},{"key":"2025060208125618100_jiaf012-B21","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"Antinori","year":"2007","journal-title":"Neurology"},{"key":"2025060208125618100_jiaf012-B22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/13854040490501448","article-title":"Initial validation of a screening battery for the detection of HIV-associated cognitive impairment","volume":"18","author":"Carey","year":"2004","journal-title":"Clin Neuropsychol"},{"key":"2025060208125618100_jiaf012-B23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/13803390490510031","article-title":"Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection","volume":"26","author":"Carey","year":"2004","journal-title":"J Clin Exp Neuropsychol"},{"key":"2025060208125618100_jiaf012-B24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/13803395.2010.535504","article-title":"Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change","volume":"33","author":"Cysique","year":"2011","journal-title":"J Clin Exp Neuropsychol"},{"key":"2025060208125618100_jiaf012-B25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/13854040590967559","article-title":"Demographically adjusted normative standards for new indices of performance on the Paced Auditory Serial Addition Task (PASAT)","volume":"20","author":"Gonzalez","year":"2006","journal-title":"Clin Neuropsychol"},{"key":"2025060208125618100_jiaf012-B26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.acn.2005.07.008","article-title":"A battery approach for measuring neuropsychological change","volume":"21","author":"Woods","year":"2006","journal-title":"Arch Clin Neuropsychol"},{"key":"2025060208125618100_jiaf012-B27","volume-title":"BDI-II, Beck Depression Inventory: manual","author":"Beck","year":"1996","edition":"2nd ed"},{"key":"2025060208125618100_jiaf012-B28","first-page":"614","article-title":"The Composite International Diagnostic Interview (CIDI) web site","volume":"77","author":"Nelson","year":"1999","journal-title":"Bull World Health Organ"},{"key":"2025060208125618100_jiaf012-B29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-4613-2211-5_4","volume-title":"Advances in clinical neuropsychology","author":"Chelune","year":"1986"},{"key":"2025060208125618100_jiaf012-B30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"2025060208125618100_jiaf012-B31","year":"2007"},{"key":"2025060208125618100_jiaf012-B32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0b013e3181cbdaff","article-title":"Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension","volume":"53","author":"Falutz","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025060208125618100_jiaf012-B33","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/brain\/awab462","article-title":"Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus","volume":"145","author":"Ellis","year":"2022","journal-title":"Brain"},{"key":"2025060208125618100_jiaf012-B34","doi-asserted-by":"crossref","first-page":"e0140358","DOI":"10.1371\/journal.pone.0140358","article-title":"Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat","volume":"10","author":"Mangili","year":"2015","journal-title":"PLoS One"},{"key":"2025060208125618100_jiaf012-B35","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2165\/11202240-000000000-00000","article-title":"Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy","volume":"71","author":"Dhillon","year":"2011","journal-title":"Drugs"},{"key":"2025060208125618100_jiaf012-B36","doi-asserted-by":"crossref","first-page":"e008675","DOI":"10.1161\/JAHA.118.008675","article-title":"Relationship between changes in fat and lean depots following weight loss and changes in cardiovascular disease risk markers","volume":"7","author":"Clifton","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025060208125618100_jiaf012-B37","doi-asserted-by":"crossref","first-page":"e0190862","DOI":"10.1371\/journal.pone.0190862","article-title":"Effectiveness of nationwide screening and lifestyle intervention for abdominal obesity and cardiometabolic risks in Japan: the metabolic syndrome and comprehensive lifestyle intervention study on nationwide database in Japan (MetS ACTION-J study)","volume":"13","author":"Nakao","year":"2018","journal-title":"PLoS One"},{"key":"2025060208125618100_jiaf012-B38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12933-022-01706-2","article-title":"Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes","volume":"21","author":"Orsi","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2025060208125618100_jiaf012-B39","doi-asserted-by":"crossref","first-page":"e114112","DOI":"10.1371\/journal.pone.0114112","article-title":"Surrogate markers of visceral adiposity in young adults: waist circumference and body mass index are more accurate than waist hip ratio, model of adipose distribution and visceral adiposity index","volume":"9","author":"Borruel","year":"2014","journal-title":"PLoS One"},{"key":"2025060208125618100_jiaf012-B40","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2147\/NDT.S145245","article-title":"Sex differences in obesity and cognitive function in a cognitively normal aging Chinese Han population","volume":"13","author":"Li","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025060208125618100_jiaf012-B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12868-023-00840-1","article-title":"Sex differences in response to obesity and caloric restriction on cognition and hippocampal measures of autophagic-lysosomal transcripts and signaling pathways","volume":"25","author":"Baer","year":"2024","journal-title":"BMC Neurosci"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf012\/61443882\/jiaf012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/5\/1230\/61443882\/jiaf012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/5\/1230\/61443882\/jiaf012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:13:11Z","timestamp":1748866391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/5\/1230\/7954598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf012","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,15]]},"published":{"date-parts":[[2025,1,15]]}}}